Omega Therapeutics Inc
NASDAQ:OMGA

  • LAST PRICE
    2.1200
  • TODAY'S CHANGE (%)
    0.1200 (6.0000%)
  • Bid / Lots
    2.0200/ 3
  • Ask / Lots
    2.1200/ 35
  • Open / Previous Close
    2.0200 / 2.0000
  • Day Range
    1.9600
    2.1400
  • 52 Week Range
    1.3000
    8.6900
  • Volume
    295,709

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
OMGA
Omega Therapeutics Inc
110.3M
-1.3x
---
YBGJ
Yubo International Biotech Ltd
109.0M
-87.7x
---
CTXR
Citius Pharmaceuticals Inc
110.1M
-2.6x
---
IMUX
Immunic Inc
110.8M
-0.7x
---
ACET
Adicet Bio Inc
110.9M
-0.4x
---
ARMP
Armata Pharmaceuticals Inc
98.3M
-1.2x
---
As of 2024-06-11

Company Information

Omega Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in the development of a programmable epigenomic mRNA medicine to treat or cure a broad range of diseases. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, called epigenomic controllers, or ECs, to target EpiZips for precision epigenomic control. Its pipeline consists of programs that span oncology, regenerative medicine, and multigenic diseases including immunologic and cardiometabolic conditions. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunologic and cardiometabolic conditions, and regenerative medicine.

Contact Information

Headquarters
140 First Street, Suite 501CAMBRIDGE, MA, United States 02141
Phone
617-949-4360
Fax
302-655-5049

Executives

Independent Chairman of the Board
Christian Schade
President, Chief Executive Officer, Director
Mahesh Karande
Principal Financial Officer, Senior Vice President - Finance, Principal Accounting Officer
Barbara Chan
Chief Legal and Administrative Officer
Ling Zeng
Chief Scientific Officer
Thomas Mccauley

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$110.3M
Revenue (TTM)
$4.9M
Shares Outstanding
55.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.67
Book Value
$1.05
P/E Ratio
-1.3x
Price/Sales (TTM)
22.3
Price/Cash Flow (TTM)
---
Operating Margin
-1,921.30%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.